Skip to Main Content
 

Global Search Box

 
 
 
 

Files

File List


Thesis Watts Final PDF.pdf (1.05 MB)

ETD Abstract Container

Abstract Header

An Evaluation of Intranasal Ketorolac in an Untreated Endodontic Pain Model

Watts, Kathryn Teal
http://orcid.org/0000-0002-8973-0207
http://rave.ohiolink.edu/etdc/view?acc_num=osu1532509409975989

Abstract Details

2018, Master of Science, Ohio State University, Dentistry.
Introduction: Previously, ketorolac was available for primary use only via intravenous and intramuscular routes. Its availability in intranasal form offers an alternative route of administration that patients can self-administer. The purpose of this study was to compare the efficacy of intranasal ketorolac (Sprix®) to a combination of ibuprofen/acetaminophen in an acute pain model of untreated endodontic patients experiencing moderate to severe pain and symptomatic apical periodontitis. Methods and Materials: Seventy patients experiencing moderate to severe pain, a pulpal diagnosis of symptomatic irreversible pulpitis or symptomatic necrosis, and a periapical diagnosis of symptomatic apical periodontitis participated. Patients were randomly divided into two groups and received either 31.5 mg intranasal ketorolac and placebo capsules (n=36) or 1000 mg acetaminophen/600 mg ibuprofen capsules and a mock nasal spray (n=34). Patients recorded perceived pain scores on a VAS every 15 minutes for 240 minutes. Time to 50% pain relief, time to first sign of pain relief, and to meaningful pain relief were recorded and the data analyzed. Results: A decline in reported pain was observed until 120 minutes post-dosing, after which reported pain remained relatively constant. Fifty percent pain relief was achieved at 70 minutes and 87 minutes for the acetaminophen/ibuprofen/mock nasal spray group and placebo/intranasal ketorolac group, respectively, with no significant difference between the groups. Conclusions: The effectiveness of intranasal ketorolac was not significantly different from that of a 1000 mg acetaminophen/600 mg ibuprofen combination. Intranasal ketorolac provides a non-narcotic alternative and an additional route of medication administration to practicing clinicians.
Melissa Drum, D.D.S., M.S. (Advisor)
Al Reader, D.D.S., M.S. (Committee Member)
John Nusstein, D.D.S., M.S. (Committee Member)
Sara Fowler, D.D.S., M.S. (Committee Member)
Mike Beck, D.D.S., M.S. (Committee Member)
79 p.
Dentistry
intranasal ketorolac; Sprix; preoperative pain

Recommended Citations

Citations

  • Watts, K. T. (2018). An Evaluation of Intranasal Ketorolac in an Untreated Endodontic Pain Model [Master's thesis, Ohio State University]. OhioLINK Electronic Theses and Dissertations Center. http://rave.ohiolink.edu/etdc/view?acc_num=osu1532509409975989

    APA Style (7th edition)

  • Watts, Kathryn. An Evaluation of Intranasal Ketorolac in an Untreated Endodontic Pain Model. 2018. Ohio State University, Master's thesis. OhioLINK Electronic Theses and Dissertations Center, http://rave.ohiolink.edu/etdc/view?acc_num=osu1532509409975989.

    MLA Style (8th edition)

  • Watts, Kathryn. "An Evaluation of Intranasal Ketorolac in an Untreated Endodontic Pain Model." Master's thesis, Ohio State University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=osu1532509409975989

    Chicago Manual of Style (17th edition)

osu1532509409975989
138
© 2018, all rights reserved.
This open access ETD is published by The Ohio State University and OhioLINK.